Your browser doesn't support javascript.
loading
Shedding light on therapeutics in alopecia and their relevance to COVID-19.
Fagan, Nicole; Meah, Nekma; York, Katherine; Bokhari, Laita; Fletcher, Godfrey; Chen, Gang; Tobin, Desmond J; Messenger, Andrew; Irvine, Alan D; Sinclair, Rodney; Wall, Dmitri.
Affiliation
  • Fagan N; School of Medicine, Trinity College Dublin, Dublin, Ireland. Electronic address: nifagan@tcd.ie.
  • Meah N; Sinclair Dermatology, Melbourne, Australia.
  • York K; Department of Dermatology, Netcare Greenacres Hospital, Port Elizabeth, South Africa.
  • Bokhari L; Sinclair Dermatology, Melbourne, Australia.
  • Fletcher G; National and International Skin Registry Solutions (NISR), Charles Institute of Dermatology, University College Dublin, Dublin, Ireland.
  • Chen G; Centre for Health Economics, Monash University, Melbourne, Australia.
  • Tobin DJ; The Charles Institute of Dermatology, University College Dublin, Dublin, Ireland.
  • Messenger A; Department of Dermatology, Royal Hallamshire Hospital, Sheffield, United Kingdom.
  • Irvine AD; Department of Dermatology, Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
  • Sinclair R; Sinclair Dermatology, Melbourne, Australia.
  • Wall D; National and International Skin Registry Solutions (NISR), Charles Institute of Dermatology, University College Dublin, Dublin, Ireland; Hair Restoration Blackrock, Dublin, Ireland.
Clin Dermatol ; 39(1): 76-83, 2021.
Article de En | MEDLINE | ID: mdl-33972056
As of July 9, 2020, there were more than 12 million confirmed cases of coronavirus disease 2019 (COVID-19) across the globe, with more than 550,000 deaths. Many European countries, including Belgium, the United Kingdom, Italy, and Spain, have had the highest numbers of fatalities per capita. This indicates the potential for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus to overwhelm even the most advanced health care systems despite extreme societal interventions. Since its emergence, SARS-CoV-2 has disseminated across the globe, affecting the structure of global societies, infrastructure, and economies. Patients with alopecia are a diverse group who, for various indications, are prescribed a number of antimicrobials and antiandrogen treatments in addition to immunomodulatory therapies such as hydroxychloroquine, oral corticosteroids, and a range of broad immunosuppressants. These drugs are being scrutinized for their capacity to potentially affect SARS-CoV-2 outcomes. We examine these treatments and highlight the critical role that patient registries will play in generating real-world evidence to assess their impact on COVID-19 outcomes.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Alopécie / Traitements médicamenteux de la COVID-19 Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Clin Dermatol Année: 2021 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Alopécie / Traitements médicamenteux de la COVID-19 Type d'étude: Prognostic_studies Limites: Humans Langue: En Journal: Clin Dermatol Année: 2021 Type de document: Article Pays de publication: États-Unis d'Amérique